CYP2C19 genotypes were determined and clopidogrel response was tested. The primary endpoints included symptomatic or silent ischemic events, and bleeding events. The secondary endpoint was clinical ...

For instance, there is limited evidence to support the use of testing for the CYP2C19 genotype in stroke patients who are receiving chronic clopidogrel therapy. Furthermore, many pharmacogenetics ...

The participants who had an abnormal variant of the CYP2C19 liver enzyme and received clopidogrel showed a 5.9% event rate, versus a 4.4% event rate in those who received genotype-guided ticagrelor ...

The CYP2C19 gene affects how clopidogrel is metabolized, and individuals with certain genetic variants may experience reduced effectiveness of the drug. Updated guidelines now recommend ...

Clopidogrel: Loss-of-function variants in the hepatic CYP2C19 system have been found ... although prospective studies evaluating the benefits of genotype guided dosing are needed.

Background to the Genedrive® CYP2C19 test The Genedrive ... test of choice for use in the NHS for CYP2C19 genotype guided prescribing of Clopidogrel in Ischaemic stroke (IS) and Transient ...

we are well positioned to capitalise on the emerging clinical pharmacogenetics area of point of care CYP2C19 genotype-guided clopidogrel treatment both domestically and internationally ...

Some studies have suggested that patients who have a certain genetic liver enzyme abnormality (known as cytochrome P450 2C19 [CYP2C19] *2 or *3 allele) may have a reduced ability to activate ...

for CYP2C19 genotype guided prescribing of the antiplatelet drug clopidogrel used in ischemic stroke (IS) and transient ischemic attack (TIA) cases. The test operates using a non-invasive cheek swab ...